<DOC>
	<DOCNO>NCT02062294</DOCNO>
	<brief_summary>This retrospective review evaluate efficacy Valcyte ( valganciclovir ) prevent Cytomegalovirus ( CMV ) disease D+/R- liver transplant recipient . Data eligible patient collect 6 month follow transplantation .</brief_summary>
	<brief_title>An Observational Study Valcyte ( Valganciclovir ) D+/R- Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<criteria>Liver transplant recipient , &gt; /= 16 year age Transplantation January 2004 June 2009 CMV seronegative recipient ( R ) receive liver transplant seropositive donor ( D+ ) Valganciclovir therapy least 70 day begin within 10 day post transplantation Assessment CMV disease status within first 6 month post transplantation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>